BIOA Latest Press Releases

-- March 24, 2026 --

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 Globe Newswire 9:00 AM

-- March 23, 2026 --

New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD congress PRNewswire 3:50 AM

-- February 19, 2026 --

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference Globe Newswire 4:30 PM

-- January 21, 2026 --

BioAge Announces Pricing of Upsized $115.0 Million Public Offering Globe Newswire 10:30 PM

-- January 20, 2026 --

BioAge Announces Proposed Public Offering Globe Newswire 4:01 PM

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 Globe Newswire 9:00 AM

-- January 12, 2026 --

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk Globe Newswire 9:00 AM

-- December 4, 2025 --

BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor Globe Newswire 9:00 AM

-- November 25, 2025 --

BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference Globe Newswire 4:30 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software